NASDAQ:AXDX Accelerate Diagnostics (AXDX) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free AXDX Stock Alerts $0.89 -0.06 (-6.34%) (As of 10:58 AM ET) Add Compare Share Share Today's Range$0.89▼$0.9550-Day Range$0.74▼$1.1952-Week Range$0.73▼$11.90Volume1,351 shsAverage Volume113,236 shsMarket Capitalization$19.18 millionP/E RatioN/ADividend YieldN/APrice Target$1.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Accelerate Diagnostics alerts: Email Address Accelerate Diagnostics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside7.5% Upside$1.00 Price TargetShort InterestBearish2.90% of Float Sold ShortDividend StrengthN/ASustainability-1.62Upright™ Environmental ScoreNews Sentiment0.40Based on 4 Articles This WeekInsider TradingSelling Shares$83,235 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.27) to ($1.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.70 out of 5 starsMedical Sector383rd out of 908 stocksAnalytical Instruments Industry11th out of 26 stocks 1.3 Analyst's Opinion Consensus RatingAccelerate Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAccelerate Diagnostics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.90% of the float of Accelerate Diagnostics has been sold short.Short Interest Ratio / Days to CoverAccelerate Diagnostics has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Accelerate Diagnostics has recently increased by 27.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAccelerate Diagnostics does not currently pay a dividend.Dividend GrowthAccelerate Diagnostics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAccelerate Diagnostics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" product. See details.Environmental SustainabilityThe Environmental Impact score for Accelerate Diagnostics is -1.62. Previous Next 2.4 News and Social Media Coverage News SentimentAccelerate Diagnostics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Accelerate Diagnostics this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Accelerate Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accelerate Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,235.00 in company stock.Percentage Held by Insiders43.60% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.14% of the stock of Accelerate Diagnostics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Accelerate Diagnostics are expected to grow in the coming year, from ($2.27) to ($1.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accelerate Diagnostics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accelerate Diagnostics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Accelerate Diagnostics Stock (NASDAQ:AXDX)Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.Read More AXDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXDX Stock News HeadlinesApril 19, 2024 | insidertrades.comInsider Selling: Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Sells 26,735 Shares of StockApril 18, 2024 | insidertrades.comJack Phillips Sells 26,545 Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) StockApril 26, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 11, 2024 | insidertrades.comAccelerate Diagnostics, Inc. (NASDAQ:AXDX) CFO David Patience Sells 13,296 SharesApril 6, 2024 | insidertrades.comAccelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Sells $13,980.56 in StockApril 21, 2024 | americanbankingnews.comAccelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Sells $20,853.30 in StockApril 20, 2024 | americanbankingnews.comAccelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.comApril 20, 2024 | investing.comAccelerate Diagnostics CEO sells shares worth over $20kApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 18, 2024 | investing.comAccelerate Diagnostics CEO sells shares worth over $22kApril 17, 2024 | finance.yahoo.comAccelerate Rural Indiana announces $30 million awardApril 15, 2024 | theglobeandmail.comClosing Bell: Accelerate Onechoice Altnv Portfolio ETF down on Thursday (ONEC)April 3, 2024 | theglobeandmail.comClosing Bell: Accelerate Enhanced CDN Bm Alt Fund ETF down on Wednesday (ATSX)April 2, 2024 | finance.yahoo.comAccelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2023 Earnings Call TranscriptMarch 30, 2024 | seekingalpha.comAccelerate Diagnostics Inc. (AXDX) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | theglobeandmail.comClosing Bell: Accelerate Onechoice Altnv Portfolio ETF up on Wednesday (ONEC)March 29, 2024 | theglobeandmail.comClosing Bell: Accelerate Onechoice Altnv Portfolio ETF down on Wednesday (ONEC)March 29, 2024 | msn.comAccelerate Property Fund Sells Cherry Lane Shopping Centre to Cadastral AssetsMarch 29, 2024 | finanznachrichten.deAccelerate Diagnostics, Inc.: Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 29, 2024 | finance.yahoo.comQ4 2023 Accelerate Diagnostics Inc Earnings CallMarch 28, 2024 | investorplace.comAXDX Stock Earnings: Accelerate Diagnostics Misses EPS, Misses Revenue for Q4 2023March 28, 2024 | benzinga.comRecap: Accelerate Diagnostics Q4 EarningsMarch 28, 2024 | msn.comAccelerate Diagnostics GAAP EPS of -$0.89 misses by $0.27, revenue of $3M misses by $0.45MMarch 28, 2024 | prnewswire.comAccelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 27, 2024 | benzinga.comA Preview Of Accelerate Diagnostics's EarningsMarch 27, 2024 | msn.comHow to Accelerate Metabolism with Ease (Even After 40)March 27, 2024 | msn.comPAVmed Q4 2024 Earnings PreviewSee More Headlines Receive AXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/26/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:AXDX CUSIPN/A CIK727207 Webacceleratediagnostics.com Phone(520) 365-3100Fax520-269-6580Employees179Year FoundedN/APrice Target and Rating Average Stock Price Target$1.00 High Stock Price Target$1.00 Low Stock Price Target$1.00 Potential Upside/Downside+6.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,620,000.00 Net Margins-454.95% Pretax Margin-503.92% Return on EquityN/A Return on Assets-170.54% Debt Debt-to-Equity RatioN/A Current Ratio2.03 Quick Ratio1.76 Sales & Book Value Annual Sales$12.06 million Price / Sales1.68 Cash FlowN/A Price / Cash FlowN/A Book Value($1.37) per share Price / Book-0.68Miscellaneous Outstanding Shares21,660,000Free Float12,218,000Market Cap$20.27 million OptionableOptionable Beta0.52 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Jack Phillips (Age 58)CEO, President & Director Comp: $595kMr. Lawrence Michael Mertz (Age 62)Chief Technology Officer Comp: $329.23kMr. David Patience (Age 38)CFO, Principal Financial Officer & Principal Accounting Officer Ms. Maya GowriSenior VP & Head of OperationsLaura PiersonInvestor Relations OfficerMr. John MeduriChief Strategy OfficerMr. Chris ThodeSenior Vice President of US CommercialMs. Rita BoukamelSenior VP & Head of EMEAMore ExecutivesKey CompetitorsCue HealthNASDAQ:HLTHTalis BiomedicalNASDAQ:TLISSingular Genomics SystemsNASDAQ:OMICTelesis BioNASDAQ:TBIOPrecipioNASDAQ:PRPOView All CompetitorsInsiders & InstitutionsGriffin Asset Management Inc.Bought 134,530 shares on 4/17/2024Ownership: 6.252%Jack PhillipsSold 26,735 sharesTotal: $20,853.30 ($0.78/share)Jack PhillipsSold 26,545 sharesTotal: $22,828.70 ($0.86/share)Larry Michael MertzSold 13,984 sharesTotal: $12,166.08 ($0.87/share)David PatienceSold 13,296 sharesTotal: $11,567.52 ($0.87/share)View All Insider TransactionsView All Institutional Transactions AXDX Stock Analysis - Frequently Asked Questions Should I buy or sell Accelerate Diagnostics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AXDX shares. View AXDX analyst ratings or view top-rated stocks. What is Accelerate Diagnostics' stock price target for 2024? 2 Wall Street analysts have issued 1 year price targets for Accelerate Diagnostics' shares. Their AXDX share price targets range from $1.00 to $1.00. On average, they expect the company's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price. View analysts price targets for AXDX or view top-rated stocks among Wall Street analysts. How have AXDX shares performed in 2024? Accelerate Diagnostics' stock was trading at $3.92 on January 1st, 2024. Since then, AXDX stock has decreased by 76.3% and is now trading at $0.93. View the best growth stocks for 2024 here. Are investors shorting Accelerate Diagnostics? Accelerate Diagnostics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 373,700 shares, an increase of 27.7% from the March 31st total of 292,600 shares. Based on an average daily trading volume, of 86,400 shares, the days-to-cover ratio is presently 4.3 days. Currently, 2.9% of the shares of the stock are short sold. View Accelerate Diagnostics' Short Interest. When is Accelerate Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our AXDX earnings forecast. How were Accelerate Diagnostics' earnings last quarter? Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its quarterly earnings results on Thursday, March, 28th. The medical research company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.27. The medical research company earned $3.03 million during the quarter, compared to the consensus estimate of $3.80 million. When did Accelerate Diagnostics' stock split? Accelerate Diagnostics shares reverse split on Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Accelerate Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU). Who are Accelerate Diagnostics' major shareholders? Accelerate Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional investors include Griffin Asset Management Inc. (6.25%). Insiders that own company stock include David Patience, Hany Massarany, Jack Phillips, Jack W Schuler, Larry Michael Mertz, Ron Price and Steven Reichling. View institutional ownership trends. How do I buy shares of Accelerate Diagnostics? Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AXDX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accelerate Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
